Innovative BioMedical Devices
bioMD Limited ABN 35 088 221 078

Level 11, 225 St Georges Terrace
Perth, Western Australia 6000

PO Box 7209, Cloisters Square
Western Australia 6850

Telephone (08) 9262 6777
Facsimile (08) 9322 3433
www.biomd.com.au

bioMD LIMITED

ANNOUNCEMENT TO THE AUSTRALIAN STOCK EXCHANGE

21 October 2005

Company Announcements Office
Australian Stock Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000

CHAIRMAN'S ADDRESS AT GENERAL MEETING

Please find attached a copy of the Chairman's Address to be given at the general meeting of shareholders to be held today, 21 October 2005, at London House, 216 St Georges Terrace, Perth, commencing at 10.00am.

Yours faithfully

C. Bentley

Caroline Bentley
Company Secretary

CHAIRMAN'S ADDRESS

SECOND Annual General Meeting of bioMD Ltd

21 October 2005 – London House, 216 St Georges Terrace, Perth WA

OVERVIEW:

Since my report to you at last year's AGM, the biotechnology sector has fallen out of favour with investors. In particular companies involved in the syringe and needle sector have all seen dramatic falls in their market value.

It is the view of our management team that the sector is attracting interest again for value investment opportunities. The syringe and needle sector, from a sophisticated investor's point of view, will continue to require fully informed explanation against "emotion-lead" investment from the wider market.

During the year we have continued with the development of the three main products – the POP Safety Injection Needle, Prefilled Safety Syringe and the MD Safety Syringe. Our Research Collaboration with CSIRO is continuing into the Material Development phase for the project.

The Company has been trading at cash backing for 6 months which does not apply any value for our projects at all. While this is upsetting, it does provide the scenario of re-rating when the market responds to success within our projects or any new investments that may eventuate.

During the year, Management has been actively looking for new opportunities in the cutting-edge of Medical Device Technology. They have evaluated implantable Medical Devices in areas such as Women's Health, the Wound Care market, Tissue Engineering and Biological Implants.

Two of these technologies/products are continuing to be evaluated.

- ❖ The Board is investigating potential acquisitions in the Medical Device area in order to expand and lower its risk profile.

- ❖ Your Company is now considering the further development of its Injection Therapy Products as a none-core part of its business.
  Shareholders should not be greatly concerned as these products will continue to be developed to "proof of concept stage" prior to a final commercialisation or Licensing decision being taken at a later date.

- ❖ The Value proposition for bioMD will be strategically directed to new medical device technologies and the Collaboration with CSIRO.

Turning to the financial results for the year ended 30 June 2005:

RESULTS:

The operating loss of the Company for the year ended 30 June 2005 amounted to $1,767,760 (2004: $650,347). This includes a one-off write down of $1,090,574 related to costs of IP acquired and equipment that has been superseded in the development process of the suite of products. Due to the uncertainty of future cash flows, the Directors have resolved to make a conservative decision to write-off the carrying value of the IP held. The Company continues to develop the underlying technology and is of the opinion that there is potential for future profits from the development of the products through either sale or exploitation to generate shareholder wealth. The development of the products is highly prospective and the write-down does not in any way reflect any decision regarding the future viability of the products; it has been done on a conservative basis for accounting purposes.

At June 30, bioMD Limited had cash reserves of $3.36million. Under our current budget for the next 12 months, bioMD is in a strong financial position, which, given the biotechnology sector weakness, is a credit to the board and management.

bioMD continues to maintain its Quality Assurance certification with the appropriate standards for regulatory product approvals both within Australia and overseas.

CONCLUSION:

I would now like to get onto the business of the meeting.

Thank you.